<DOC>
	<DOCNO>NCT00099359</DOCNO>
	<brief_summary>Giving anti-HIV medication baby bear HIV positive mother right birth low baby ' risk contracting HIV . This study ass safety efficacy two different combination anti-HIV medication compare one drug standard regimen prevent mother baby transmission . The one drug standard treatment two combination study : 1 ) zidovudine , 2 ) zidovudine/nevirapine 3 ) zidovudine/lamivudine/nelfinavir .</brief_summary>
	<brief_title>Trial Three Neonatal Antiretroviral Regimens Prevention Intrapartum HIV Transmission</brief_title>
	<detailed_description>Despite notable reduction perinatal transmission HIV-1 antiretroviral therapy intervention , perinatal transmission continue occur rate 20-30 % among pregnant woman identify HIV-1-infected and/or provide antiretroviral therapy . The optimum treatment strategy prevention transmission HIV-1 infant born woman unknown . No trial evaluate efficacy neonatal antiretroviral therapy alone observational data suggest benefit zidovudine ( ZDV ) therapy give infant begin within 48 hour birth continue six week . This protocol compare safety efficacy three antiretroviral regimen administer neonatal period : Arm A- ZDV , Arm B- ZDV plus nevirapine ( NVP ) , Arm C- ZDV plus nelfinavir ( NFV ) lamivudine ( 3TC ) . Two regimen select base expected antiretroviral activity , pharmacokinetic data , toxicity profile . Standard care ( 6 week ZDV ) alone compare 6 week ZDV plus either 3 dos NVP 2 week 3TC NFV . Arm B ( ZDV + NVP ) regimen expect provide best profile factor efficacy , safety , cost , acceptability convenience consider . The comparison Arms B C also considerable interest since 2-drug Arm B easier implement less expensive triple drug Arm C. Although triple drug therapy recommend post-exposure prophylaxis needle-stick injury high-risk circumstance , unknown whether triple drug arm provide good efficacy 2-drug arm post-exposure prophylaxis infant . This open-label study expect accrue 1731 infant woman identify labor HIV positive HIV positive receive antiretroviral medication pregnancy . If eligible infant randomize birth one three aforementioned treatment arm . Medical history , social , demographic , physical exam , RNA T- lymphocyte data collect mother delivery visit . The infant birth visit return 1-week , 2-week , 4-week , 3-month final 6-month visit . Infant evaluation include : medical history physical exam , DNA testing , CBC liver function test , cell long-term storage RNA/CD4/CD8 test HIV positive . The initial study drug dos give infant hospital . Mothers administer infant ' remain treatment dose home depend ability .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Infants meet follow criterion eligible study : Mother know HIV1infected prior labor identify time labor &lt; 48 hour postpartum . HIV1 infection purpose enrollment study define : ( ) Single positive HIV1 rapid test mother infant ; ( b ) Historical documentation positive HIV1 diagnostic test confirm repeat diagnostic testing HIV1 accord country guideline mother ( write documentation test result must present medical record ) . Maternal write informed consent study participation . Mother receive antiretroviral therapy current pregnancy prior onset labor delivery ; woman may receive intravenous oral ZDV labor . Women may receive antiretroviral therapy previous pregnancy prevention vertical HIV1 transmission . Infant &lt; 48 hour old . Infant may receive 48 hour ZDV standard care study enrollment . Infants meet follow criterion exclude study : Extreme prematurity ( &lt; 32 week gestation ) . Birth weight &lt; 1500 gram . Presence lifethreatening condition . Inability take oral medication throughout first 48 hour life ( must able receive oral medication age 48 hour ) . Maternal inability provide inform consent lack conscious state , psychiatric condition , language barrier . Mother receive antiretroviral therapy labor delivery intravenous oral ZDV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Days</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>Perinatal</keyword>
	<keyword>Prevention</keyword>
	<keyword>Transmission</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Epivir</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>ZDV</keyword>
	<keyword>NVP</keyword>
	<keyword>3TC</keyword>
	<keyword>NFV</keyword>
	<keyword>Viracept</keyword>
	<keyword>Viramune</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>